Clinical Trial Update: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Phase 2]

View source ↗

Summary

A multicenter Phase 2 trial is evaluating whether lowering lipoprotein(a) with Pelacarsen (TQJ230) can influence the progression of calcific aortic valve stenos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aortic Stenosis
• Calcific Aortic Valve Stenosis

Drugs mentioned

• Pelacarsen (pelacarsen)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Aortic Stenosis | Phase 2 | Status: RECRUITING